

# LY310762

**Catalog No: tcsc3261**



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

192927-92-7

**Formula:**

$C_{24}H_{28}ClFN_2O_2$

**Pathway:**

Neuronal Signaling;GPCR/G Protein

**Target:**

5-HT Receptor;5-HT Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 44$  mg/mL (102.10 mM)

**Observed Molecular Weight:**

430.94

## Product Description


LY310762 is a 5-HT1D receptor antagonist with  $K_i$  of 249 nM, having a weaker affinity for 5-HT1B receptor.

IC50 value: 249 nM ( $K_i$ ) [1]

Target: 5-HT1D

in vitro: LY310762 has a higher affinity for the guinea pig 5-HT<sub>1D</sub> receptor than for the 5-HT<sub>1B</sub> receptor. LY310762 potentiates the potassium-induced [<sup>3</sup>H]5-HT outflow from guinea pig cortical slices with an EC<sub>50</sub> of 30 nM. The maximum potentiation of the potassium-induced outflow which is obtained with LY310762 is about 40% [1]. LY310762 blocks the decreased EPSC amplitude induced by Sumatriptan [2].

in vivo: Systemic administration of LY310762 (10 mg/kg i.p.) produces a further significant enhancement in the 5-HT response to fluoxetine (20 mg/kg i.p.) when compared to animals receiving a control vehicle injection. In fluoxetine treated animals, levels of 5-HT increases from 312±43% to a maximum of 683% after LY310762. In control animals, levels of 5-HT remains unchanged (250%). LY310762 administered alone also significantly increases basal levels of 5-HT above vehicle controls, reaching a maximum of 258% compared to the pre-injection control [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!